πŸ‡ΊπŸ‡Έ FDA
Patent

US 11013808

Clinical formulations

granted A61KA61K31/7004A61K31/728

Quick answer

US patent 11013808 (Clinical formulations) held by Astellas Institute for Regenerative Medicine expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Astellas Institute for Regenerative Medicine
Grant date
Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K31/7004, A61K31/728, A61K33/06, A61K33/14